Literature DB >> 30248202

Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs.

Jennifer Le1, John S Bradley2,3.   

Abstract

The selection of the right antibiotic and right dose necessitates clinicians understand the contribution of pharmacokinetic variability stemming from age-related physiologic maturation and the pharmacodynamics to optimize drug exposure for clinical response. The complexity of selecting the right dose arises from the multiplicity of pediatric age groups, from premature neonates to adolescents. Body size and age (which relate to organ function) must be incorporated to optimize antibiotic dosing in this vulnerable population. In the effort to optimize and individualize drug dosing regimens, clinical pharmacometrics that incorporate population-based pharmacokinetic modeling, Bayesian estimation, and Monte Carlo simulations are utilized as a quantitative approach to understanding and predicting the pharmacology and clinical and microbiologic efficacy of antibiotics. In addition, opportunistic study designs and alternative blood sampling strategies can serve as practical approaches to ensure successful conduct of pediatric studies. This review article examines relevant literature on optimization of antibiotic pharmacotherapy in pediatric populations published within the last decade. Specific pediatric antibiotic data, including beta-lactam antibiotics, aminoglycosides, and vancomycin, are critically evaluated.
© 2018, The American College of Clinical Pharmacology.

Entities:  

Keywords:  Bayesian methods; Monte Carlo simulation; Pharmacokinetic; aminoglycosides; antibiotics; antimicrobials; beta-lactams; ceftaroline; neonates; opportunistic study; pediatrics; pharmacodynamic; vancomycin

Mesh:

Substances:

Year:  2018        PMID: 30248202     DOI: 10.1002/jcph.1128

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Pharmacokinetics of ticarcillin-clavulanate in premature infants.

Authors:  Kevin M Watt; Christoph P Hornik; Stephen J Balevic; Gratias Mundakel; C Michael Cotten; Barrie Harper; Daniel K Benjamin; Ravinder Anand; Matthew Laughon; P Brian Smith; Michael Cohen-Wolkowiez
Journal:  Br J Clin Pharmacol       Date:  2019-03-06       Impact factor: 4.335

Review 2.  How to Treat Sepsis in the Background of Resistance?: Role of Pharmacodynamics / Pharmacokinetics in Treating Sepsis.

Authors:  Mohit Agrawal; Ashok Rattan
Journal:  Indian J Pediatr       Date:  2020-01-14       Impact factor: 1.967

3.  Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis.

Authors:  Jennifer Le; Rachel G Greenberg; Daniel K Benjamin; YoungJun Yoo; Kanecia O Zimmerman; Michael Cohen-Wolkowiez; Kelly C Wade
Journal:  J Pediatric Infect Dis Soc       Date:  2021-05-28       Impact factor: 5.235

4.  Population pharmacokinetics and dose optimization of vancomycin in neonates.

Authors:  Soon Min Lee; Seungwon Yang; Soyoung Kang; Min Jung Chang
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

Review 5.  Review of Scavenged Sampling for Sustainable Therapeutic Drug Monitoring: Do More With Less.

Authors:  Stef Schouwenburg; Robin F J van der Klip; Tim J L Smeets; Nicole G M Hunfeld; Robert B Flint; Matthijs de Hoog; Henrik Endeman; Birgit C P Koch; Enno D Wildschut; Alan Abdulla
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

Review 6.  Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update.

Authors:  Franziska Schneider; André Gessner; Nahed El-Najjar
Journal:  Antibiotics (Basel)       Date:  2022-01-28

Review 7.  Beta-Lactams Therapeutic Monitoring in Septic Children-What Target Are We Aiming for? A Scoping Review.

Authors:  Ronaldo Morales Junior; Gabriela Otofuji Pereira; Gustavo Magno Baldin Tiguman; Vanessa D'Amaro Juodinis; João Paulo Telles; Daniela Carla de Souza; Silvia Regina Cavani Jorge Santos
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.